Evidence map›Paper›PMID 27092550›Full record

ArticlePloS one2016

Aberrant Levels of Hematopoietic/Neuronal Growth and Differentiation Factors in Euthyroid Women at Risk for Autoimmune Thyroid Disease.

Elske T Massolt, Grigoris Effraimidis, Tim I M Korevaar, Wilmar M Wiersinga, W Edward Visser, Robin P Peeters, Hemmo A Drexhage

Abstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Observational
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Elske T MassoltDivision of Endocrinology, Department of Internal Medicine, Erasmus MC, 3000 CA, Rotterdam, The Netherlands.
Grigoris EffraimidisInternal Medicine Department, Endocrinology Section, Nykøbing Falster Hospital, Fjordvej 15, 4800, Nykøbing Falster, Denmark.
Tim I M KorevaarDivision of Endocrinology, Department of Internal Medicine, Erasmus MC, 3000 CA, Rotterdam, The Netherlands.
Wilmar M WiersingaAcademical Medical Center, University of Amsterdam, 1105 AZ, Amsterdam, The Netherlands.
W Edward VisserDivision of Endocrinology, Department of Internal Medicine, Erasmus MC, 3000 CA, Rotterdam, The Netherlands.
Robin P PeetersDivision of Endocrinology, Department of Internal Medicine, Erasmus MC, 3000 CA, Rotterdam, The Netherlands.
Hemmo A DrexhageDepartment of Immunology, Erasmus MC, 3000 CA, Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSubjects at risk for major mood disorders have a higher risk to develop autoimmune thyroid disease (AITD) and vice-versa, implying a shared pathogenesis. In mood disorder patients, an abnormal profile of hematopoietic/neuronal growth factors is observed, suggesting that growth/differentiation abnormalities of these cell lineages may predispose to mood disorders. The first objective of our study was to investigate whether an aberrant profile of these hematopoietic/neuronal growth factors is also detectable in subjects at risk for AITD. A second objective was to study the inter relationship of these factors with previously determined and published growth factors/cytokines in the same subjects.

methodsWe studied 64 TPO-Ab-negative females with at least 1 first- or second-degree relative with AITD, 32 of whom did and 32 who did not seroconvert to TPO-Ab positivity in 5-year follow-up. Subjects were compared with 32 healthy controls (HCs). We measured serum levels of brain-derived neurotrophic factor (BDNF), Stem Cell Factor (SCF), Insulin-like Growth Factor-Binding Protein 2 (IGFBP-2), Epidermal Growth Factor (EGF) and IL-7 at baseline.

resultsBDNF was significantly lower (8.2 vs 18.9 ng/ml, P<0.001), while EGF (506.9 vs 307.6 pg/ml, P = 0.003) and IGFBP-2 (388.3 vs 188.5 ng/ml, P = 0.028) were significantly higher in relatives than in HCs. Relatives who seroconverted in the next 5 years had significantly higher levels of SCF than non-seroconverters (26.5 vs 16.7 pg/ml, P = 0.017). In a cluster analysis with the previously published growth factors/cytokines SCF clustered together with IL-1β, IL-6 and CCL-3, of which high levels also preceded seroconversion.

conclusionRelatives of AITD patients show aberrant serum levels of 4 hematopoietic/neuronal growth factors similar to the aberrancies found in mood disorder patients, suggesting that shared growth and differentiation defects in both the hematopoietic and neuronal system may underlie thyroid autoimmunity and mood disorders. A distinct pattern of four inter correlating immune factors in the relatives preceded TPO-Ab seroconversion in the next 5 years.

Indexed as

Brain-Derived Neurotrophic FactorCase-Control StudiesFemaleFollow-Up StudiesGrowth Differentiation FactorsHematopoietic Cell Growth FactorsHumansInsulin-Like Growth Factor Binding Protein 2Interleukin-1betaInterleukin-6Interleukin-7Mood DisordersNerve Growth FactorsRiskThyroid GlandThyroiditis, AutoimmuneBrain-Derived Neurotrophic FactorGrowth Differentiation FactorsHematopoietic Cell Growth FactorsInsulin-Like Growth Factor Binding Protein 2Interleukin-1betaInterleukin-6Interleukin-7Nerve Growth Factors

Identifiers

PMID27092550
PMCPMC4836766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.